Brown Brothers Harriman & Co’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.06M Buy
59,318
+8,556
+17% +$1.31M 0.05% 151
2025
Q4
$7M Buy
50,762
+1,822
+4% +$239K 0.04% 146
2025
Q3
$6.28M Sell
48,940
-1,237
-2% -$151K 0.04% 144
2025
Q2
$6.07M Sell
50,177
-11,362
-18% -$1.28M 0.04% 139
2025
Q1
$6.86M Sell
61,539
-1,506
-2% -$160K 0.05% 134
2024
Q4
$6.13M Buy
63,045
+10,113
+19% +$1.08M 0.04% 138
2024
Q3
$6.09M Sell
52,932
-2,988
-5% -$339K 0.04% 136
2024
Q2
$5.95M Buy
55,920
+7,823
+16% +$785K 0.04% 132
2024
Q1
$4.65M Sell
48,097
-150
-0.3% -$15.4K 0.04% 149
2023
Q4
$4.87M Sell
48,247
-13,045
-21% -$1.26M 0.04% 142
2023
Q3
$6.24M Sell
61,292
-1,346
-2% -$137K 0.06% 124
2023
Q2
$6.32M Sell
62,638
-1,100
-2% -$110K 0.05% 115
2023
Q1
$5.86M Sell
63,738
-7,277
-10% -$636K 0.05% 103
2022
Q4
$6.44M Sell
71,015
-2,578
-4% -$217K 0.06% 97
2022
Q3
$5.59M Sell
73,593
-10,102
-12% -$837K 0.05% 100
2022
Q2
$7.08M Sell
83,695
-13,094
-14% -$1.15M 0.06% 95
2022
Q1
$8.49M Sell
96,789
-27,201
-22% -$2.36M 0.06% 95
2021
Q4
$10.8K Sell
123,990
-18,014
-13% -$1.5M 0.06% 89
2021
Q3
$11.6K Sell
142,004
-10,544
-7% -$949K 0.07% 81
2021
Q2
$13.9K Sell
152,548
-45,346
-23% -$4.04M 0.08% 75
2021
Q1
$16.9K Sell
197,894
-82,295
-29% -$7.39M 0.11% 72
2020
Q4
$26.5M Sell
280,189
-61,208
-18% -$5.35M 0.18% 61
2020
Q3
$29.7M Sell
341,397
-3,613,526
-91% -$313M 0.21% 59
2020
Q2
$345M Sell
3,954,923
-137,049
-3% -$11.8M 2.6% 12
2020
Q1
$337M Sell
4,091,972
-295,413
-7% -$26.4M 2.75% 13
2019
Q4
$415M Sell
4,387,385
-354,912
-7% -$31.8M 2.65% 12
2019
Q3
$412M Sell
4,742,297
-1,206,226
-20% -$108M 2.75% 12
2019
Q2
$543M Sell
5,948,523
-910,694
-13% -$77.1M 3.61% 8
2019
Q1
$591M Sell
6,859,217
-374,313
-5% -$30M 4.07% 7
2018
Q4
$556M Sell
7,233,530
-1,154,896
-14% -$89.9M 4.21% 7
2018
Q3
$648M Sell
8,388,426
-599,257
-7% -$44.3M 4.01% 8
2018
Q2
$608M Sell
8,987,683
-972,108
-10% -$67.1M 3.73% 8
2018
Q1
$722M Sell
9,959,791
-298,068
-3% -$22.7M 4.16% 8
2017
Q4
$772M Sell
10,257,859
-981,185
-9% -$74M 4.24% 8
2017
Q3
$865M Sell
11,239,044
-88,969
-0.8% -$6.72M 4.61% 6
2017
Q2
$847M Sell
11,328,013
-721,086
-6% -$51.1M 4.59% 6
2017
Q1
$802M Sell
12,049,099
-194,841
-2% -$13M 4.35% 6
2016
Q4
$799M Buy
12,243,940
+1,729,617
+16% +$112M 4.37% 6
2016
Q3
$744M Sell
10,514,323
-299,817
-3% -$21.8M 3.95% 8
2016
Q2
$800M Buy
10,814,140
+29,263
+0.3% +$2.02M 4.15% 6
2016
Q1
$700M Buy
10,784,877
+1,021,558
+10% +$69.5M 3.61% 9
2015
Q4
$753M Sell
9,763,319
-605,989
-6% -$48.1M 3.97% 8
2015
Q3
$854M Sell
10,369,308
-483,646
-4% -$43M 4.35% 7
2015
Q2
$956M Sell
10,852,954
-401,743
-4% -$36.9M 4.47% 5
2015
Q1
$994M Sell
11,254,697
-330,967
-3% -$29.4M 4.5% 5
2014
Q4
$962M Sell
11,585,664
-1,060,149
-8% -$87.9M 4.05% 6
2014
Q3
$1.07B Sell
12,645,813
-70,321
-0.6% -$5.69M 4.29% 6
2014
Q2
$1.03B Sell
12,716,134
-1,107,204
-8% -$87.1M 4.18% 5
2014
Q1
$1.05B Buy
13,823,338
+55,506
+0.4% +$4.04M 4.5% 5
2013
Q4
$992M Sell
13,767,832
-969,793
-7% -$67.4M 4.48% 5
2013
Q3
$1.01B Buy
14,737,625
+212,864
+1% +$14.1M 4.79% 4
2013
Q2
$920M Buy
+14,524,761
New +$945M 4.36% 4

Other funds holding NVS

Brown Brothers Harriman & Co's NVS Position: Q1 2026 in Review

Brown Brothers Harriman & Co increased its Novartis (NVS) stake by 17% in Q1 2026, buying an estimated $1.31M and bringing the position to 59,318 shares worth $9.06M. The position accounts for 0.05% of the portfolio, ranked #151.

Brown Brothers Harriman & Co first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.07B in Q3 2014. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Brown Brothers Harriman & Co held 59,318 shares of Novartis worth $9.06M as of Q1 2026.
  • Brown Brothers Harriman & Co bought 8,556 Novartis shares in Q1 2026, an estimated $1.31M.
  • Novartis made up 0.05% of Brown Brothers Harriman & Co's portfolio in Q1 2026, its #151 holding.
  • Brown Brothers Harriman & Co first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • Brown Brothers Harriman & Co's Novartis position peaked at $1.07B in Q3 2014.
  • 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2026, filed 14 May 2026.